louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT06432673: The Attractive 2 Trial - Pharmacokinetics of ATR-258 Oral Capsule vs. Oral Solution Formulations in Healthy Volunteers
Official title: The Attractive 2 Trial - An Open-label, Randomised, 2-period Cross-over Trial to Assess the Pharmacokinetics of ATR-258 Oral Capsule vs. Oral Solution Formulations in Healthy Volunteers
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Type2diabetes
Lead sponsor: Atrogi AB
Sponsor class: INDUSTRY
First posted: 2024-05-29
Enrollment: 21
Sex: ALL
Minimum age (years): 18
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: TREATMENT

Brief summary: This is a single-centre, open-label, randomised, 2-period cross-over, Phase 1 comparative trial to assess the ATR-258 pharmacokinetic (PK) parameters of an oral capsule formulation in comparison with an oral solution formulation, both given as single doses to healthy volunteers. The order of treatment, i.e., the treatment sequence capsule - solution or solution - capsule, will be randomised.


Eligibility criteria: Inclusion Criteria:

* Provision of informed consent
* Body mass index ≥ 18.5 and ≤ 30.0
* Medically healthy participant
* Willing to use of double barrier contraceptive method if of childbearing potential

Exclusion Criteria:

* History or clinical manifestation of any clinically significant disease
* History of dysphagia or any other swallowing disorder
* Current smokers or users of nicotine products
* History or manifestation of drug abuse, alcohol abuse and/or excessive intake of alcohol

Primary outcomes:
measure: Area under the plasma concentration versus time curve (AUC)
timeFrame: 48 hours
measure: Peak Plasma Concentration (Cmax)
timeFrame: 48 hours
Secondary outcomes:
measure: Time to maximum plasma concentration (Tmax)
timeFrame: 48 hours
measure: Half life in plasma (T1/2)
timeFrame: 48 hours
measure: Apparent total body clearance following extravascular administration (CL/F)
timeFrame: 48 hours
measure: Volume of distribution following extravascular administration (Vz/F)
timeFrame: 48 hours
measure: Adverse events
timeFrame: 7 days post last dose
Other outcomes:
Locations:
city: Uppsala
country: Sweden
facility: Clinical Trial Consultants AB
Study officials:
affiliation: Atrogi AB
name: Erik Waara
role: STUDY_CHAIR
References:
Clinical trial NCT04346173: Palatal Lengthening Using Buccinator Myomucosal Flaps with Furlow Z-plasty Technique for Primary Cleft Palate Repair
Official title: Palatal Lengthening Using Buccinator Myomucosal Flaps with Furlow Z-plasty Technique for Primary Cleft Palate Repair (A Clinical Study)
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Cleft Palate, Unilateral, Complete
Lead sponsor: Alexandria University
Sponsor class: OTHER
First posted: 2020-04-15
Enrollment: 12
Sex: ALL
Minimum age (years): 9
Maximum age (years): 18
Standard ages: CHILD
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: : Cleft palate is a congenital deformity caused by abnormal facial development during intra-uterine life. Worldwide, the prevalence of cleft lip/palate is about 1:1000 live births.

The levator vela palatini muscles are malpositioned sagittally, running postero-anteriorly and inserted onto the posterior edge of the hard palate in cleft palate patients . This configuration prevents the muscle from exerting its upward, backward, and lateral pull.

Various modalities have been described with major refinements over the past 30 years. Gradually, cleft surgeons began to appreciate the importance of dissection and retro-positioning of the levator muscle on improving speech outcomes.

Furlow was the first to describe the palatoplasty technique, in which the levator muscle is dissected and freely released from its abnormal position and retro-positioned in a Z-plasty lengthening technique without dissection on the hard palate. However , among the problems that have been raised concerning the Furlow palatoplasty is the limitation of the procedure in wide clefts. Furthermore, the possibility of higher fistula rate associated with the technique.

These considerations have led to modified palatal lengthening by buccinator myomucosal flaps which is this study working on.


Eligibility criteria: Inclusion Criteria:

* Patients in the age frame between 9 months and 18 months.
* Cleft palate alone or cleft lip and palate patients.
* Patients who have not done any previous palatal repair
* Haemoglobin level above 10 grams.
* Weight above 10 pounds.

Exclusion Criteria:

* Syndromic patients.
* Medically compromised patients contradicting operation.

Primary outcomes:
measure: palatal lengthening
timeFrame: immediately postoperative
Secondary outcomes:
Other outcomes:
Locations:
city: Alexandria
country: Egypt
facility: Faculty of Dentistry, Alexandria University
Study officials:
References:
Clinical trial NCT00547573: Determine Safety and Effectiveness of Tadalafil in Asian Men When Taken as Needed for Getting and Keeping an Erection
Official title: A Multinational, Randomized, Double-Blind, Parallel, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Tadalafil Administered "On Demand" to Asian Men With Erectile Dysfunction
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE3
Conditions: Impotence
Lead sponsor: Eli Lilly and Company
Sponsor class: INDUSTRY
Collaborators: name: ICOS Corporation
First posted: 2007-10-22
Enrollment: 367
Sex: MALE
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Study to determine if tadalafil works better than placebo for Asian men having trouble getting or keeping an erection.


Eligibility criteria: Inclusion Criteria:

* History of erection problems
* Anticipate a monogamous female sexual relationship
* Abstain from other erection treatments at least 4 weeks before first dose and throughout the study
* Must be able to make required sexual intercourse attempts

Exclusion Criteria:

* Other primary sexual disorders
* History of radical prostatectomy or other pelvic surgery that affected being able to have an erection
* History of penile implant or clinically significant penile deformity
* Nitrate use
* Certain heart problems

Primary outcomes:
measure: IIEF Erectile Function Domain score from Questions 1-5 and 15. SEP Diary responses to Questions 2-3 and the entire Diary for baseline and endpoint scores.
timeFrame: 4, 8, and 12 weeks
Secondary outcomes:
measure: IIEF questions and scores, Global Assessment Questions, Patient's SEP Diary
timeFrame: 12 weeks
Other outcomes:
Locations:
city: Beijing
country: China
facility: For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak to your personal physician.
Study officials:
affiliation: Eli Lilly and Company
name: Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, ESt)
role: STUDY_DIRECTOR
References:
Clinical trial NCT01142973: The Clinical Course of Coronary Artery Disease in Coronary Multidetector Computed Tomographic Angiogram
Official title: Prognostic Role of Coronary Artery plaquEs in Patients With Suspected Coronary Artery Disease Using Multislice of Computed Tomography (PREDICT)
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Atherosclerosis
Cardiovascular Diseases
Coronary Artery Disease
Lead sponsor: Inje University
Sponsor class: OTHER
First posted: 2010-06-14
Enrollment: 5000
Sex: ALL
Minimum age (years): 18
Maximum age (years): 85
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: CROSS_SECTIONAL
Sampling method: NON_PROBABILITY_SAMPLE
Study population: present typical/atypical chest pain

Brief summary: Study Type: Observational Study Design: Observational Model: Defined Population Observational Model: Natural History Time Perspective: Longitudinal Time Perspective: Prospective

Detailed description: The natural history of individual plaques is unknown and needs to be established. Multidetector computed tomography (MDCT) angiography is a useful noninvasive imaging modality for assessing coronary plaque. Using MDCT, the researchers prospectively investigate the relationship between the presence of coronary plaques and cardiovascular events

Eligibility criteria: Inclusion Criteria:

* Patients with known or suspected coronary artery disease

Exclusion Criteria:

* Irregular heart beat
* Known allergy towards the contrast agent
* Renal dysfunction
* Impossible breath-hold
* Acute coronary syndrome patient

Primary outcomes:
measure: Major cardiovascular events
timeFrame: 1 years after the MDCT-scan
Secondary outcomes:
measure: all causes of hospitalization
timeFrame: 1 years after the MDCT-scan
Other outcomes:
Locations:
city: Goyang
country: Korea, Republic of
facility: Ilsan Paik hospital
Study officials:
affiliation: Inje univ. ilsan paik hospital
name: Sung Uk Kwon, M.D.
role: PRINCIPAL_INVESTIGATOR
References:
citation: Kim JB, Rogers IS, Kwon SU. Presence of plaques predicts worse outcomes in multi-detector computed tomography in patients with stable chest pain syndrome. Int J Cardiol. 2014 May 15;173(3):570-2. doi: 10.1016/j.ijcard.2014.03.118. Epub 2014 Mar 21. No abstract available.
Clinical trial NCT04881331: Intraoperative Tissue Identification by Analyzing Surgical Smoke
Official title: Intraoperative Tissue Identification by Analyzing Surgical Smoke
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Breast Cancer
Lead sponsor: Tampere University Hospital
Sponsor class: OTHER
First posted: 2021-05-11
Enrollment: 20
Sex: FEMALE
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_ONLY
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients undergoing breast conserving surgery for histologically confirmed malignancy of the breast. There is no upper limit for participation.

Brief summary: SurgiNose is a single-center, non-randomized feasibility study aiming to evaluate the feasibility of intraoperative tissue analysis using differential mobility of surgical smoke generated with electrocautery.

Patients receive standard-of-care breast conserving surgery.

Detailed description: The increasing number of breast cancer survivors and their longevity has emphasized the importance of aesthetic and functional outcomes of cancer surgery and increased pressure for the surgical treatment to achieve negative margins with minimal removal of healthy tissue.

Surgical smoke has been successfully utilized in tissue identification in laboratory conditions by using a system based on differential mobility spectrometry (DMS) that could provide a seamless margin assessment method.

In this study, a DMS-based tissue smoke analysis system will be used intraoperatively in 20 breast cancer surgeries to assess its feasibility in tissue identification. The effect of the system on complications and duration of surgeries is also studied. The surgeries are recorded with a head-worn camera system for visual annotation of the operated tissue types to enable classification of the measurement files by supervised learning.

Eligibility criteria: Inclusion Criteria:

* Histologically confirmed primary malignancy of the breast

Exclusion Criteria:

-

Primary outcomes:
measure: Discrimination rate of healthy tissue types encountered during surgery
timeFrame: During the procedure
Secondary outcomes:
measure: Surgical time
timeFrame: During the procedure
measure: Complications
timeFrame: 30 days after surgery.
Other outcomes:
Locations:
city: Tampere
country: Finland
facility: TAYS Hatanpää
state: Pirkanmaa
Study officials:
References:
citation: Sutinen M, Kontunen A, Karjalainen M, Kiiski J, Hannus J, Tolonen T, Roine A, Oksala N. Identification of breast tumors from diathermy smoke by differential ion mobility spectrometry. Eur J Surg Oncol. 2019 Feb;45(2):141-146. doi: 10.1016/j.ejso.2018.09.005. Epub 2018 Oct 15.
Clinical trial NCT03274973: Study to Assess Long-term Effectiveness of Zomacton® and Treatment Adherence in Patients With Growth Hormone Deficiency or Ullrich-Turner Syndrome
Official title: A Prospective Non-Interventional Study to Assess Long-term Effectiveness of Zomacton® and Factors Affecting Adherence in Patients With Growth Hormone Deficiency or Growth Retardation Due to Ullrich-Turner Syndrome
Study type: OBSERVATIONAL
Overall status: TERMINATED
Conditions: Growth Disorders
Lead sponsor: Ferring Pharmaceuticals
Sponsor class: INDUSTRY
First posted: 2017-09-07
Enrollment: 4
Sex: ALL
Maximum age (years): 18
Standard ages: CHILD
ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Pediatric outpatient clinic

Brief summary: Assessment of long-term effectiveness of ZOMACTON in treatment of Growth Hormone Deficiency or growth retardation due to Ullrich-Turner Syndrome and assessment of compliance and adherence, optionally with the aid of an electronic app or patient diary.


Eligibility criteria: Inclusion Criteria:

* Pediatric patients (\< 18 years) with growth hormone deficiency or growth retardation due to Ullrich-Turner-Syndrome
* Patients already receiving or who have been prescribed Zomacton® de novo according to its German label; the decision to prescribe Zomacton® was made independently from participation and prior to enrollment in this study.
* Patient and their parents (or legal representatives) who are willing and able to provide signed informed consent for use of their personal data.

Exclusion Criteria:

* Participation in an interventional clinical study within the last 30 days prior to baseline visit or during the follow-up period

Primary outcomes:
measure: Linear growth (change in height)
timeFrame: Over the first 12 months (month 0, 3, 6, 9 and 12)
Secondary outcomes:
Other outcomes:
Locations:
city: Kiel
country: Germany
facility: Klinik fuer Allgemeine Paediatrie der Christian-Albrechts-Universitaet zu Kiel (there might be other sites in this country)
Study officials:
affiliation: Ferring Pharmaceuticals
name: Global Clinical Compliance
role: STUDY_DIRECTOR
References:
Clinical trial NCT00653731: Effective Strategies for Dementia Care
Official title: Testing Three Interventions for Clinical Effectiveness in Long Term Care Residents With Dementia: Snoezelen, Structured Reminiscence Therapy, 10-minutes Activation. A Cluster-randomized Controlled Trial.
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Dementia
Cognitive Impairment
Keywords: dementia
snoezelen
structured reminiscence therapy
10-minutes activation
apathy
Lead sponsor: Martin-Luther-Universität Halle-Wittenberg
Sponsor class: OTHER
Collaborators: name: German Federal Ministry of Education and Research
First posted: 2008-04-07
Enrollment: 327
Sex: ALL
Minimum age (years): 55
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: SUPPORTIVE_CARE

Brief summary: The purpose of this study is to determine whether the interventions of Snoezelen, structured reminiscence therapy and 10-minutes activation are effective to reduce apathy in long term care residents with dementia.

Detailed description: Design:

Cluster-randomized controlled trial with 20 nursing homes in Saxony and Saxony-Anhalt (Germany).

Eligibility criteria: Inclusion Criteria:

* Dementia
* Informed consent by legal guardian
* MMSE ≤ 24

Exclusion Criteria:

* Korsakoff's syndrome
* Age ≤ 55 years
* Cognitive impairment other cause than dementia

Primary outcomes:
measure: Apathy Evaluation Scale (Marin et al. 1991)
timeFrame: 12 months
Secondary outcomes:
measure: Neuropsychiatric Inventory (Cummings 1997)
timeFrame: 3, 6 and 12 months
measure: Apathy Evaluation Scale (Marin et al. 1991)
timeFrame: 3 and 6 months
measure: Staff Observation Aggression Scale (Nijman et al. 1997)
timeFrame: 3,6 and 12 months
measure: Nottingham Health Profile (Bureau-Chalot et al. 2002) staff-related measurement
timeFrame: 6 and 12 months
measure: Smiley Analogue Scale for Well-Being
timeFrame: 3, 6 and 12 months
measure: PASTA (Zimber 2001) staff-related measurement
timeFrame: 6 and 12 months
Other outcomes:
Locations:
city: Halle
country: Germany
facility: Institut für Gesundheits- und Pflegewissenschaft, Medizinische Fakultät, Martin-Luther-Universität Halle-Wittenberg
state: SAN
Study officials:
affiliation: Martin-Luther-University Halle-Wittenberg
name: Johann Behrens, PhD
role: PRINCIPAL_INVESTIGATOR
References:
citation: Berg A, Sadowski K, Beyrodt M, Hanns S, Zimmermann M, Langer G, Becker C, Lautenschlager C, Behrens J. Snoezelen, structured reminiscence therapy and 10-minutes activation in long term care residents with dementia (WISDE): study protocol of a cluster randomized controlled trial. BMC Geriatr. 2010 Jan 31;10:5. doi: 10.1186/1471-2318-10-5.
Clinical trial NCT03121131: CT and Radiologist RCT
Official title: How Important is a Clinical Data for a Radiologist? A Double-Blinded Randomized Controlled Trial of Radiologic Interpretation of Ventral Hernias Following Selectively-Provided Clinical Information
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Hernia
Lead sponsor: The University of Texas Health Science Center, Houston
Sponsor class: OTHER
First posted: 2017-04-19
Enrollment: 7
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: DIAGNOSTIC

Brief summary: The use of computed tomography (CT) imaging is rapidly increasing in healthcare. Despite physicians' growing reliance on radiological assessments, however, the reliability and accuracy of reads are highly variable. Inconsistencies may result from multiple factors.

The researchers hypothesize that the presence and quality of clinical information will affect radiologist's assessment of CT scans for the presence/absence of a ventral hernia.


Eligibility criteria: Participants are radiologists at LBJ Hospital.

Primary outcomes:
measure: Hernia detected on CT
timeFrame: CT taken within 1 year
Secondary outcomes:
Other outcomes:
Locations:
city: Houston
country: United States
facility: UT Health at Lyndon B. Johnson General Hospital
state: Texas
Study officials:
References:
citation: Cherla DV, Bernardi K, Blair KJ, Chua SS, Hasapes JP, Kao LS, Ko TC, Matta EJ, Moses ML, Shiralkar KG, Surabhi VR, Tammisetti VS, Viso CP, Liang MK. Importance of the physical exam: double-blind randomized controlled trial of radiologic interpretation of ventral hernias after selective clinical information. Hernia. 2019 Oct;23(5):987-994. doi: 10.1007/s10029-018-1856-3. Epub 2018 Nov 14.
Clinical trial NCT01576731: Study Comparing Two Alternatives of Antiretroviral Therapy as Post-exposure Prophylaxis to HIV-1: Tenofovir + Emtricitabine + Lopinavir/Ritonavir Versus Tenofovir + Emtricitabine + Raltegravir (RAL-PEP)
Official title: Open Randomized Study Comparing Two Alternatives of Antiretroviral Therapy as Post-exposure Prophylaxis to HIV-1: Tenofovir + Emtricitabine + Lopinavir/Ritonavir Versus Tenofovir + Emtricitabine + Raltegravir
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE4
Conditions: HIV Infection
Keywords: HIV Infection
Postexposure prophylaxis
Lead sponsor: Hospital Clinic of Barcelona
Sponsor class: OTHER
First posted: 2012-04-12
Enrollment: 240
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: PREVENTION

Brief summary: As a measure of secondary prophylaxis, and with the final objective of avoiding the infection, it has been suggested to use antiretroviral therapy. This is known as post-exposure prophylaxis (PEP).

Although there are different recommendations, almost every guideline recommend using 3 drugs as PEP both in USA and Europe.

Toxicity is one of the main limitations of PEP. Side effects during PEP are very usual, are attributed mainly to PI and are the main reasons for poor adherence or lost of follow-up.

A current standard regimen is AZT+3TC (Combivir®) or tenofovir+emtricitabine (Truvada®) plus the PI lopinavir/r. Toxicity associated with this regimens are high (31-85% of cases),with a high tolerability, a integrase inhibitor (raltegravir)could be an adequate drug for PEP.


Eligibility criteria: Inclusion Criteria:

* Potentially sexual exposition to HIV

Exclusion Criteria:

* Pregnancy
* Source case with antiretroviral resistances
* any treatment contraindicated with the drugs of study

Primary outcomes:
measure: Proportion of patients dropping out before the 28 days of postexposure prophylaxis
timeFrame: 28 days
Secondary outcomes:
Other outcomes:
Locations:
city: Barcelona
country: Spain
facility: Hospital Clínic of Barcelona
Study officials:
affiliation: Consultant senior
name: Felipe Garcia, PhD
role: PRINCIPAL_INVESTIGATOR
References:
citation: Leal L, Leon A, Torres B, Inciarte A, Lucero C, Mallolas J, Laguno M, Martinez-Rebollar M, Gonzalez-Cordon A, Manzardo C, Rojas J, Pich J, Arnaiz JA, Gatell JM, Garcia F; RALPEP Study Group. A randomized clinical trial comparing ritonavir-boosted lopinavir versus raltegravir each with tenofovir plus emtricitabine for post-exposure prophylaxis for HIV infection. J Antimicrob Chemother. 2016 Jul;71(7):1987-93. doi: 10.1093/jac/dkw049. Epub 2016 Mar 18.
Clinical trial NCT03551431: Comparison of Efficacy Between Suggestion Method During Video EEG Recording by Verbal Suggestion in Isolation and Verbal Suggestion Along With Cotton Swab or Tuning Fork for Inducing the Paroxysmal Event in Children Aged 5 to 18 Years With Suspected Psychogenic Nonepileptic Events
Official title: Comparison of Efficacy Between Suggestion Method During Video EEG Recording by Verbal Suggestion in Isolation and Verbal Suggestion Along With Cotton Swab or Tuning Fork for Inducing the Paroxysmal Event in Children Aged 5 to 18 Years With Suspected Psychogenic Nonepileptic Events
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: EEG, Psychogenic Non Epileptic Events
Lead sponsor: All India Institute of Medical Sciences
Sponsor class: OTHER
First posted: 2018-06-11
Enrollment: 25
Sex: ALL
Minimum age (years): 5
Maximum age (years): 18
Standard ages: CHILD
ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Intervention model description: Open labeled, randomized controlled Non-inferiority study with three parallel arms: video EEG with verbal suggestion only, cotton swab with verbal suggestion and tuning fork along with verbal suggestion
Primary purpose: DIAGNOSTIC

Brief summary: In this study we are going to compare efficacy between suggestion method during video EEG recording by verbal suggestion in isolation and verbal suggestion along with cotton swab or tuning fork for inducing the paroxysmal event in children aged 5 to 18 years with suspected psychogenic nonepileptic events. Still there is paucity of data regarding the optimum method for video EEG by suggestion for psychogenic nonepileptic events. We are planning to recruit 25 children aged 5 to 18 years in each of the three arms after taking informed consent from the guardian and then they will be subjected to video EEG by any one of the three suggestion methods.


Eligibility criteria: Inclusion Criteria: Children between 5 and 18 years of age with suspected diagnosis of psychogenic nonepileptic events -

Exclusion Criteria: Children with paroxysmal events, who will be later diagnosed as having epilepsy or movement disorder

-

Primary outcomes:
measure: Percentage of children in each group, in whom the paroxysmal event could be reproduced by suggestion
timeFrame: 30 minutes
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
References: